Sir Run Run Shaw Hospital

Running trials

• Not yet recruiting

  Remote Intervention Versus Routine Monitoring in COPD Patients With Chronic Hypercapnia Receiving Home Non-invasive Respiratory Support

  NCT07751003· Sir Run Run Shaw Hospital· Source

• Recruiting

  Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy

  NCT07789184· Phase 3· Hua Huang, MD, PhD· Source

• Not yet recruiting

  Hs-CRP-Guided Colchicine Treatment Targets in Very-High-Risk Patients With Coronary Artery Disease After PCI (TARGET-CHD)

  NCT07920133· Sir Run Run Shaw Hospital· Source

• Not yet recruiting

  Sirolimus-Coated Versus Paclitaxel-Coated Balloon for Recurrent Coronary In-Stent Restenosis After Prior Paclitaxel-Coated Balloon Treatment (SPRIT)

  NCT07920055· Sir Run Run Shaw Hospital· Source

• Recruiting

  Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

  NCT07323095· Phase 2· Atom Therapeutics Co., Ltd· Source

• Recruiting

  A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

  NCT07811193· Phase 2· Vividion Therapeutics, Inc.· Source

• Not yet recruiting

  Study on the Impact of Decolonization Treatment of Pneumocystis Jirovecii on the Frequency of Acute Exacerbation in COPD

  NCT07665359· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  Transcutaneous Electrical Acustimulation on Postoperative Bowel Function Recovery in Elderly Patients

  NCT07574502· Sir Run Run Shaw Hospital· Source

• Recruiting

  Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD

  NCT07632677· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Source

• Enrolling by invitation

  Left Atrial Appendage Closure With Versus Without Pulsed Field Ablation in Atrial Fibrillation Patients With Mild Symptoms and High Stroke Risk

  NCT07453940· Sir Run Run Shaw Hospital· Source

• Recruiting

  A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

  NCT07474727· Phase 2· Multitude Therapeutics Inc.· Source

• Recruiting

  A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

  NCT07365995· Phase 3· BioNTech SE· Source

• Active, not recruiting

  Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer

  NCT07512674· Phase 2· Sir Run Run Shaw Hospital· Source

• Not yet recruiting

  To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

  NCT07406438· Phase 1· Shenzhen Kexing Pharmaceutical Co., Ltd.· Source

• Recruiting

  Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule

  NCT07508618· Phase 4· Sir Run Run Shaw Hospital· Source

• Recruiting

  A Study for HSK47388 in Participants With Ulcerative Colitis

  NCT07335055· Phase 2· Haisco Pharmaceutical Group Co., Ltd.· Source

• Not yet recruiting

  Left Ventricular Myocardial Work for Predicting Response to CRT

  NCT07319065· First Hospital of China Medical University· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma

  NCT07243691· Sir Run Run Shaw Hospital· Source

• Recruiting

  Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）

  NCT07388771· Qian Chu· Source

• Recruiting

  Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

  NCT07176650· Phase 1· Shanghai Henlius Biotech· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer

  NCT07068763· Phase 2· Sir Run Run Shaw Hospital· Source

• Recruiting

  A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

  NCT07190248· Phase 3· Merck Sharp & Dohme LLC· Source

• Not yet recruiting

  Cofrogliptin and Linagliptin as add-on Therapy to Insulin in Type 2 Diabetes

  NCT07198932· Yanbing Li· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT06979336· Phase 2· Genentech, Inc.· Source

• Active, not recruiting

  A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07169578· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection

  NCT07495215· Phase 1/2· Yinghua Xu· Source

• Recruiting

  Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease

  NCT07068438· Suzhou Hengruihongyuan Medical Technology Co. LTD· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors

  NCT07181473· Phase 1· Phrontline Biopharma· Source

• Recruiting

  A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

  NCT07060807· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  REFINE-HCM: Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy

  NCT07006493· SuZhou Sinus Medical Technologies Co.,Ltd· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  NCT07011732· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma

  NCT07105852· Phase 2· Sir Run Run Shaw Hospital· Source

• Recruiting

  A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

  NCT06962865· Phase 2· RemeGen Co., Ltd.· Source

• Recruiting

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· Phase 3· BeOne Medicines· Source

• Recruiting

  Early Endovascular Treatment in Isolated Internal Carotid Artery Occlusion

  NCT07016854· Sir Run Run Shaw Hospital· Source

• Active, not recruiting

  A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

  NCT06970743· Phase 3· BeOne Medicines· Source

• Not yet recruiting

  The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCC

  NCT06895369· Phase 2· Sir Run Run Shaw Hospital· Source

• Enrolling by invitation

  Catheter Ablation for Atrial Fibrillation in Non-Fluoroscopic Lab

  NCT06719921· Sir Run Run Shaw Hospital· Source

• Recruiting

  A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

  NCT06914128· Phase 1/2· Bayer· Source

• Recruiting

  Sleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques

  NCT06687408· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Active, not recruiting

  A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

  NCT06745323· Phase 2· Amgen· Source

• Recruiting

  A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  NCT06760819· Phase 2· Bayer· Source

• Active, not recruiting

  Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

  NCT06710132· Phase 1/2· EMD Serono Research & Development Institute, Inc.· Source

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Pfizer· Source

• Recruiting

  A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

  NCT06532006· Phase 3· Shanghai Henlius Biotech· Source

• Active, not recruiting

  A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06711900· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source

• Recruiting

  Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

  NCT06682195· Phase 2· First Affiliated Hospital of Zhejiang University· Source

• Recruiting

  Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer

  NCT06572540· Jiayuan Sun· Source

Showing 50 of 92.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer10 recruiting
• Colorectal cancer9 recruiting
• Liver and biliary tract cancer7 recruiting
• Gastric and oesophageal cancer4 recruiting
• Pancreatic cancer4 recruiting
• Atrial fibrillation3 recruiting
• Bladder cancer3 recruiting
• COPD3 recruiting
• Metastatic breast cancer3 recruiting
• Stroke3 recruiting
• Coronary artery disease2 recruiting
• Head and neck cancer2 recruiting
• Prostate cancer2 recruiting
• Type 2 diabetes2 recruiting
• Ulcerative colitis2 recruiting
• Alzheimer disease1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Crohn's disease1 recruiting
• Endometrial cancer1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Glioblastoma1 recruiting
• Heart failure1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Macular degeneration1 recruiting
• Melanoma1 recruiting
• Ovarian cancer1 recruiting
• Parkinson disease1 recruiting
• Sarcoma1 recruiting
• Schizophrenia1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects

  NCT07357831· Phase 3· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Completed

  BCD to Measure the ED95 of Remimazolam-Assisted Sedation in Arteriovenous Fistula Creation Surgery

  NCT06998732· Sir Run Run Shaw Hospital· Source

• Completed

  Assessment of the Safety and Efficacy of the Felix NeuroAI Wristband in Essential Tremor

  NCT06235190· Fasikl Inc.· Source

• Completed

  A Retrospective Observational Study of Ustekinumab Among Bio-naive Participants With Crohn's Disease in China

  NCT06082986· Xian-Janssen Pharmaceutical Ltd.· Source

• Completed

  Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study

  NCT06039748· Shenzhen Raysight Intelligent Medical Technology Co., Ltd.· Source

• Completed

  InsightPFA Trial of the LotosPFA Catheter

  NCT06014996· Insight Medtech Co., Ltd.· Source

• Completed

  A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China

  NCT05896774· Phase 1· Pfizer· Source

• Completed

  A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.

  NCT05810038· Phase 3· Pfizer· Source

• Completed

  Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease

  NCT05811442· Phase 2· Beijing Joekai Biotechnology LLC· Source

• Completed

  Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure

  NCT05949801· Phase 3· Zensun Sci. & Tech. Co., Ltd.· Source

• Completed

  Study of Telitacicept in Generalized Myasthenia Gravis

  NCT05737160· Phase 3· RemeGen Co., Ltd.· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903

  NCT06846099· Phase 1· Risen (Suzhou) Pharma Tech Co., Ltd.· Source

• Completed

  A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

  NCT05583526· Phase 3· Pfizer· Source

• Completed

  Clinical Application of Carbon Nanoparticles in Lymph Node Tracing and Surgery Guiding of Colorectal Cancer

  NCT06783985· Sir Run Run Shaw Hospital· Source

• Terminated

  A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

  NCT04963270· Phase 3· Hoffmann-La Roche· Source

• Completed

  Comparison Between Upgraded '2C3L' vs. PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation

  NCT04497376· Beijing Anzhen Hospital· Source

• Terminated

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).

  NCT04949256· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

  NCT04662710· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Lifestyle Intervention Trial in High Metabolic Risk Chinese

  NCT04714723· Chinese Academy of Sciences· Source

• Completed

  Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

  NCT04665856· Phase 3· Hoffmann-La Roche· Source

• Completed

  HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study

  NCT04694495· Zhujiang Hospital· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

  NCT04882241· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study

  NCT04889118· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)

  NCT04194203· Phase 3· Hoffmann-La Roche· Source

• Completed

  Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

  NCT04210115· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

  NCT03820986· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

  NCT03713593· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Eli Lilly and Company· Source

• Completed

  Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

  NCT03615326· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Eli Lilly and Company· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Pfizer· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

  NCT03221426· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Image Fusion of SPECT MPI and Fluoroscopy Venography to Guide LV Lead Placement for Improved CRT Response (GUIDE-CRT II)

  NCT03125720· The First Affiliated Hospital with Nanjing Medical University· Source

• Completed

  Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

  NCT02168829· Phase 4· Ottawa Heart Institute Research Corporation· Source

• Completed

  Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

  NCT02273375· Phase 3· Canadian Cancer Trials Group· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Liver and biliary tract cancer107 works · 9 trials
• Lung cancer94 works · 26 trials
• Colorectal cancer60 works · 11 trials
• Crohn's disease45 works · 4 trials
• Gastric and oesophageal cancer37 works · 12 trials
• Ulcerative colitis24 works · 8 trials
• Fatty liver disease (MASLD/MASH)23 works · 1 trial
• Thyroid cancer13 works · 1 trial
• Polycystic ovary syndrome9 works · 0 trials
• IgA nephropathy9 works · 1 trial
• Narcolepsy4 works · 0 trials
• Essential tremor3 works · 1 trial